Floatz logo

TENOFOVIR DISOPROXIL FUMARATE

HIV-1 Infection

Azienda Ospedaliera San Gerardo di MonzaSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the HIV-1 Infection cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
Efavirenz
The Cleveland Clinic
Phase 4BBB
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
RITONAVIR
Giovanni Di Perri
Phase 4BBB
NEVIRAPINE ANHYDROUS
Germans Trias i Pujol Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

TENOFOVIR DISOPROXIL FUMARATE is also rated in:

chronic hepatitis B virus infectionDormant
BBB
Indicative ·
72 / 100
View asset →
HIV infectious diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
lipodystrophyDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →